Dimerix Ltd has released a press release.
DMX-700 Data Demonstrates Effect on Key COPD Receptors
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Dimerix
- Positive Top-Line Results in DKD Phase 2 Clinical Study
- Dimerix Awarded $1 Million MRFF Funding
- Positive Top-Line Results in FSGS Phase 2a Clinical Study
- Last Patient Completes Dosing in DKD Phase 2 Clinical Study
- Dimerix Completes $5.8m Placement
Later from Dimerix
- Receipt of R&D Tax Incentive
- Positive Additional Data to Support DMX-200 Development
- ARDS in COVID-19 Patients Protocol Published
- Second Study to Include DMX-200 in COVID-19 Patients
- Dimerix Plans for Next Study in Diabetic Kidney Disease
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix